(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are ImmunoGen, Hostess Brands, and SCWorx Corp..
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | ImmunoGen (IMGN) | 29.27 | 82.25% | 2023-11-30 12:13:11 |
| 2 | Hostess Brands (TWNKW) | 3.20 | 41.59% | 2023-11-30 07:23:06 |
| 3 | SCWorx Corp. (WORX) | 2.04 | 17.24% | 2023-11-30 15:23:06 |
| 4 | Synlogic (SYBX) | 2.39 | 14.35% | 2023-11-30 01:15:06 |
| 5 | Tellurian (TELL) | 0.57 | 11.83% | 2023-11-30 03:46:06 |
| 6 | TRACON Pharmaceuticals (TCON) | 0.20 | 11.38% | 2023-11-30 03:11:05 |
| 7 | Windtree Therapeutics (WINT) | 1.04 | 10.93% | 2023-11-30 15:11:05 |
| 8 | FibroGen (FGEN) | 0.55 | 9.35% | 2023-11-30 12:12:20 |
| 9 | SpringWorks Therapeutics (SWTX) | 26.83 | 8.84% | 2023-11-30 01:12:05 |
| 10 | Neuronetics (STIM) | 1.50 | 8.7% | 2023-11-29 23:23:06 |
The three biggest losers today are Verb Technology Company, Weibo, and SRAX.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Verb Technology Company (VERBW) | 0.00 | -25% | 2023-11-30 09:15:05 |
| 2 | Weibo (WB) | 9.81 | -13.38% | 2023-11-30 12:15:42 |
| 3 | SRAX (SRAX) | 0.13 | -13.33% | 2023-11-29 22:44:06 |
| 4 | VirTra (VTSI) | 7.07 | -10.11% | 2023-11-30 13:17:06 |
| 5 | GameStop (GME) | 14.69 | -9.57% | 2023-11-30 12:55:51 |
| 6 | Fastly (FSLY) | 16.93 | -8.78% | 2023-11-30 13:01:52 |
| 7 | Sol-Gel Technologies Ltd. (SLGL) | 1.25 | -8.76% | 2023-11-29 19:13:07 |
| 8 | NeuroMetrix (NURO) | 3.75 | -8.51% | 2023-11-30 12:50:55 |
| 9 | SiNtx Technologies (SINT) | 0.36 | -8.16% | 2023-11-29 19:09:08 |
| 10 | DouYu (DOYU) | 0.72 | -7.96% | 2023-11-30 12:16:41 |
Winners today
1. ImmunoGen (IMGN) – 82.25%
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
NASDAQ ended the session with ImmunoGen jumping 82.25% to $29.27 on Friday, following the last session’s upward trend. NASDAQ dropped 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.88%.
Previous days news about ImmunoGen
- : AbbVie $10.1 billion deal to buy immunogen values the stock at a 95% premium. According to MarketWatch on Thursday, 30 November, "The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies," said AbbVie Chief Executive Richard Gonzalez.", "Under the terms of the agreement, AbbVie will pay $31.26 in cash for each ImmunoGen share outstanding, which represents a 94.6% premium above Wednesday’s closing price of $16.06. "
- Immunogen (imgn) Q3 earnings: taking a look at key metrics versus estimates. According to Zacks on Thursday, 30 November, "Here is how ImmunoGen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about ImmunoGen.
2. Hostess Brands (TWNKW) – 41.59%
Hostess Brands, Inc., a packaged food company, develops, manufactures, markets, sells, and distributes fresh sweet baked goods in the United States. It primarily offer a range of snack cakes, donuts, sweet rolls, breakfast pastries, snack pies, and related products. The company operates in two segments, Sweet Baked Goods and In-Store Bakery. The Sweet Baked Goods segment offers fresh and frozen sweet baked goods and bread products under the Hostess, Dolly Madison, Cloverhill, and Big Texas brands, as well as store branded products. The In-Store Bakery segment primarily provides Superior on Main branded eclairs, madeleines, brownies, and iced cookies in the bakery section of grocery and club stores. The company was formerly known as Gores Holdings, Inc. and changed its name to Hostess Brands, Inc. in November 2016. Hostess Brands, Inc. was founded in 1919 and is based in Lenexa, Kansas.
NASDAQ ended the session with Hostess Brands rising 41.59% to $3.20 on Friday while NASDAQ fell 0.23% to $14,226.22.
PE Ratio
Hostess Brands has a trailing twelve months price to earnings ratio of 5.15. Meaning, the purchaser of the share is investing $5.15 for every dollar of annual earnings.
Moving Average
Hostess Brands’s value is under its 50-day moving average of $3.36 and way above its 200-day moving average of $2.53.
Volume
Today’s last reported volume for Hostess Brands is 29718 which is 70.4% below its average volume of 100427.
More news about Hostess Brands.
3. SCWorx Corp. (WORX) – 17.24%
SCWorx Corp. provides software solutions for the management of health care providers' foundational business applications in the United States. The company provides services related to repair, normalization, and interoperability of information, as well as big data analytics model that provides Web portal for display, and reporting and analysis of the information contained within the data warehouse. It also offers various software solutions and services, such as virtualized item master file repair, expansion, and automation; electronic medical record management, a module that integrates the advanced data attributes created in the item master to the electronic medical records; charge description master management(CDM), a module, which assists healthcare providers by integrating the CDM data into the workflow of the hospitals purchasing systems; contract management, a module that assists healthcare providers to establish a contract management system and to provide care to patients; request for proposal automation solution; rebate management; ScanWorx, a mobile perioperative closed loop scanning solution; and data integration and warehousing, as well as solutions for integration of acquired businesses, which enable deployment of a virtual item master files. The company sells its solutions and services to hospitals and health systems through its distribution and reseller partnerships. In addition, it provides CageTix, a ticketing platform for mixed martial arts industry. Further, the company focuses on selling rapid test kits for COVID-19; and personal protective equipment. SCWorx Corp. is based in New York, New York.
NASDAQ ended the session with SCWorx Corp. jumping 17.24% to $2.04 on Friday, following the last session’s upward trend. NASDAQ slid 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, SCWorx Corp. has a trailing twelve months EPS of $-1.65.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.77%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SCWorx Corp.’s EBITDA is 0.54.
Moving Average
SCWorx Corp.’s worth is way under its 50-day moving average of $2.28 and way under its 200-day moving average of $4.08.
More news about SCWorx Corp..
4. Synlogic (SYBX) – 14.35%
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
NASDAQ ended the session with Synlogic rising 14.35% to $2.39 on Friday, after two sequential sessions in a row of gains. NASDAQ dropped 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, Synlogic has a trailing twelve months EPS of $-12.68.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -82.66%.
Moving Average
Synlogic’s worth is way above its 50-day moving average of $1.95 and way above its 200-day moving average of $0.91.
Sales Growth
Synlogic’s sales growth for the current quarter is 2400%.
Volume
Today’s last reported volume for Synlogic is 68450 which is 45.13% below its average volume of 124772.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Synlogic’s EBITDA is 9.53.
More news about Synlogic.
5. Tellurian (TELL) – 11.83%
Tellurian Inc. engages in the natural gas business worldwide. The company is developing a portfolio of natural gas production, liquefied natural gas (LNG) marketing, and infrastructure assets that includes an approximately 27.6 million tons per annum LNG export facility and an associated pipeline. It owns interests in 11,060 net acres of natural gas assets and 78 producing wells located in the Haynesville Shale trend of northern Louisiana. The company was founded in 2016 and is headquartered in Houston, Texas.
NASDAQ ended the session with Tellurian jumping 11.83% to $0.57 on Friday, after two sequential sessions in a row of gains. NASDAQ slid 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, Tellurian has a trailing twelve months EPS of $-0.22.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.06%.
Moving Average
Tellurian’s value is way under its 50-day moving average of $0.78 and way under its 200-day moving average of $1.21.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 166.7% and positive 20% for the next.
More news about Tellurian.
6. TRACON Pharmaceuticals (TCON) – 11.38%
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
NASDAQ ended the session with TRACON Pharmaceuticals rising 11.38% to $0.20 on Friday while NASDAQ slid 0.23% to $14,226.22.
Earnings Per Share
As for profitability, TRACON Pharmaceuticals has a trailing twelve months EPS of $-0.44.
Volume
Today’s last reported volume for TRACON Pharmaceuticals is 4217740 which is 1.12% above its average volume of 4170980.
Earnings Before Interest, Taxes, Depreciation, and Amortization
TRACON Pharmaceuticals’s EBITDA is -0.13.
Yearly Top and Bottom Value
TRACON Pharmaceuticals’s stock is valued at $0.20 at 01:32 EST, way under its 52-week high of $2.19 and way above its 52-week low of $0.13.
More news about TRACON Pharmaceuticals.
7. Windtree Therapeutics (WINT) – 10.93%
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.
NASDAQ ended the session with Windtree Therapeutics jumping 10.93% to $1.04 on Friday while NASDAQ dropped 0.23% to $14,226.22.
Earnings Per Share
As for profitability, Windtree Therapeutics has a trailing twelve months EPS of $-16.79.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -199.4%.
Volume
Today’s last reported volume for Windtree Therapeutics is 170078 which is 71.99% above its average volume of 98887.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Windtree Therapeutics’s EBITDA is 706.08.
Moving Average
Windtree Therapeutics’s value is under its 50-day moving average of $1.05 and way under its 200-day moving average of $2.29.
Yearly Top and Bottom Value
Windtree Therapeutics’s stock is valued at $1.04 at 01:32 EST, way under its 52-week high of $19.00 and way higher than its 52-week low of $0.86.
More news about Windtree Therapeutics.
8. FibroGen (FGEN) – 9.35%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen rising 9.35% to $0.55 on Friday, after two consecutive sessions in a row of gains. NASDAQ slid 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 37.1% and 48.1%, respectively.
Sales Growth
FibroGen’s sales growth is 14.3% for the ongoing quarter and 21.3% for the next.
Yearly Top and Bottom Value
FibroGen’s stock is valued at $0.55 at 01:32 EST, way under its 52-week high of $25.69 and way higher than its 52-week low of $0.33.
More news about FibroGen.
9. SpringWorks Therapeutics (SWTX) – 8.84%
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
NASDAQ ended the session with SpringWorks Therapeutics rising 8.84% to $26.83 on Friday, after two sequential sessions in a row of gains. NASDAQ slid 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, SpringWorks Therapeutics has a trailing twelve months EPS of $-4.87.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.55%.
Yearly Top and Bottom Value
SpringWorks Therapeutics’s stock is valued at $26.83 at 01:32 EST, way below its 52-week high of $34.16 and way higher than its 52-week low of $18.00.
Moving Average
SpringWorks Therapeutics’s value is way above its 50-day moving average of $22.77 and above its 200-day moving average of $26.32.
More news about SpringWorks Therapeutics.
10. Neuronetics (STIM) – 8.7%
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
NASDAQ ended the session with Neuronetics jumping 8.7% to $1.50 on Friday while NASDAQ dropped 0.23% to $14,226.22.
Earnings Per Share
As for profitability, Neuronetics has a trailing twelve months EPS of $-1.17.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -65.59%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 10% and 23.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.4%, now sitting on 69.23M for the twelve trailing months.
Moving Average
Neuronetics’s value is way higher than its 50-day moving average of $1.25 and way under its 200-day moving average of $2.26.
Yearly Top and Bottom Value
Neuronetics’s stock is valued at $1.50 at 01:32 EST, way below its 52-week high of $6.95 and way above its 52-week low of $1.03.
More news about Neuronetics.
Losers Today
1. Verb Technology Company (VERBW) – -25%
NASDAQ ended the session with Verb Technology Company falling 25% to $0.00 on Friday while NASDAQ fell 0.23% to $14,226.22.
Yearly Top and Bottom Value
Verb Technology Company’s stock is valued at $0.00 at 01:32 EST, below its 52-week low of $0.00.
More news about Verb Technology Company.
2. Weibo (WB) – -13.38%
Weibo Corporation, through its subsidiaries, operates as a social media platform for people to create, distribute, and discover content in the People's Republic of China. It operates in two segments, Advertising and Marketing Services; and Value-Added Services. The company offers discovery products to help users discover content on its platform; self-expression products that enable its users to express themselves on its platform; and social products to promote social interaction between users on its platform. It also provides advertising and marketing solutions, such as social display advertisements; and promoted marketing offerings, such as Fans Headline and Weibo Express promoted feeds, as well as promoted trends and search products that appear alongside user's trends discovery and search behaviors. In addition, the company offers products, such as trends, search, video/live streaming, and editing tools; content customization, copyright contents pooling, and user interaction development; and search list recommendation, trends list recommendation, and Weibo app opening advertisements. Further, it provides back-end management, traffic support, and product solutions to MCNs, unions, and e-commerce partners; open application platform for other app developers that allows users to log into third-party applications with their Weibo account for sharing third-party content on its platform; and Weibo Wallet, a product that enables platform partners to conduct interest generation activities on Weibo, such as handing out red envelops and coupons. The company was formerly known as T.CN Corporation and changed its name to Weibo Corporation in 2012. The company was founded in 2009 and is headquartered in Beijing, China. Weibo Corporation operates as a subsidiary of Sina Corporation.
NASDAQ ended the session with Weibo falling 13.38% to $9.81 on Friday while NASDAQ dropped 0.23% to $14,226.22.
Earnings Per Share
As for profitability, Weibo has a trailing twelve months EPS of $1.69.
PE Ratio
Weibo has a trailing twelve months price to earnings ratio of 5.8. Meaning, the purchaser of the share is investing $5.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.97%.
Yearly Top and Bottom Value
Weibo’s stock is valued at $9.81 at 01:32 EST, way below its 52-week low of $11.05.
Volume
Today’s last reported volume for Weibo is 7209820 which is 751.29% above its average volume of 846926.
More news about Weibo.
3. SRAX (SRAX) – -13.33%
SRAX, Inc., a technology company, focused on enhancing communications between public companies and their shareholders and investors in the United States. The company offers Sequire, a Saas platform that allows issuers to track their shareholders' behaviors and trends, then use data-driven insights to engage with shareholders across marketing channels. It also organizes and hosts investor conferences within the micro and small- cap space. The company markets and sells its services through its in-house sales and marketing team. The company was formerly known as Social Reality, Inc. and changed its name to SRAX, Inc. in August 2019. SRAX, Inc. was founded in 2009 and is headquartered in Westlake Village, California.
NASDAQ ended the session with SRAX dropping 13.33% to $0.13 on Friday, following the last session’s downward trend. NASDAQ slid 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, SRAX has a trailing twelve months EPS of $-1.09.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -174.28%.
Sales Growth
SRAX’s sales growth is 74.6% for the ongoing quarter and 23.7% for the next.
Moving Average
SRAX’s value is way under its 50-day moving average of $0.17 and way under its 200-day moving average of $0.39.
Yearly Top and Bottom Value
SRAX’s stock is valued at $0.13 at 01:32 EST, way under its 52-week high of $2.47 and way higher than its 52-week low of $0.00.
Revenue Growth
Year-on-year quarterly revenue growth declined by 22.9%, now sitting on 28.27M for the twelve trailing months.
More news about SRAX.
4. VirTra (VTSI) – -10.11%
VirTra, Inc. provides force training simulators, firearms training simulators, and driving simulators for law enforcement, military, educational, and civilian worldwide. The company's products comprise V-300 simulator, a 300 degree wrap-around screen for simulation training; V-180 simulator, a 180 degree screen for smaller spaces or budgets; V-100, a single-screen based simulator system; V-100 MIL, a single-screen small arms training simulator; and V-ST PRO, a realistic single screen firearms shooting and skills training simulator. It also offers V-Author, a software that allows users to create, edit, and train with content specific to agency's objectives; Simulated Recoil Kits, a range of realistic and reliable simulated recoil kits/weapons; and Threat-Fire, a return fire device that applies real-world stress on the trainees during simulation training. In addition, the company provides VirTra Driving Sim, a vehicle-based simulator; Virtual Interactive Coursework Training Academy, which enables law enforcement agencies to each, train, test, and sustain departmental training requirements; Subscription Training Equipment Partnership, a program that allows agencies to utilize VirTra's simulator products, accessories, and V-VICTA interactive coursework on a subscription basis; and TASER, an OC spray and low-light training devices. It sells its simulators and related products through a direct sales force and distribution partners. The company was formerly known as VirTra Systems, Inc. and changed its name to VirTra, Inc. in October 2016. VirTra, Inc. was founded in 1993 and is based in Tempe, Arizona.
NASDAQ ended the session with VirTra sliding 10.11% to $7.07 on Friday while NASDAQ slid 0.23% to $14,226.22.
Earnings Per Share
As for profitability, VirTra has a trailing twelve months EPS of $0.64.
PE Ratio
VirTra has a trailing twelve months price to earnings ratio of 11.05. Meaning, the purchaser of the share is investing $11.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.47%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VirTra’s EBITDA is 2.16.
More news about VirTra.
5. GameStop (GME) – -9.57%
GameStop Corp., a specialty retailer, provides games and entertainment products through its stores and ecommerce platforms in the United States, Canada, Australia, and Europe. The company sells new and pre-owned gaming platforms; accessories, such as controllers, gaming headsets, and virtual reality products; new and pre-owned gaming software; and in-game digital currency, digital downloadable content, and full-game downloads. It also sells collectibles comprising apparel, toys, trading cards, gadgets, and other retail products for pop culture and technology enthusiasts, as well as engages in the digital asset wallet and NFT marketplace activities. The company operates stores and ecommerce sites under the GameStop, EB Games, and Micromania brands; and pop culture themed stores that sell collectibles, apparel, gadgets, electronics, toys, and other retail products under the Zing Pop Culture brand, as well as offers Game Informer magazine, a print and digital gaming publication. The company was formerly known as GSC Holdings Corp. GameStop Corp. was founded in 1996 and is headquartered in Grapevine, Texas.
NYSE ended the session with GameStop dropping 9.57% to $14.69 on Friday, after two sequential sessions in a row of gains. NYSE rose 0.71% to $16,075.98, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, GameStop has a trailing twelve months EPS of $-0.32.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.64%.
Sales Growth
GameStop’s sales growth for the next quarter is negative 1.3%.
Previous days news about GameStop
- Gamestop stock’s best day since January driven by fresh wave of speculative bets. According to MarketWatch on Tuesday, 28 November, "Traders are piling into long-shot GameStop Inc. call options that would pay off if the stock price nearly doubles before, or shortly after, the company’s Dec. 6 earnings report, FactSet data show."
- : gamestop stock soars toward biggest 2-day gain 9 months. According to MarketWatch on Wednesday, 29 November, "Shares of GameStop Corp. ran up 15.4% toward a seven-week high, as the original "meme" stock continued to get a boost from has gained 1.7%."
More news about GameStop.
6. Fastly (FSLY) – -8.78%
Fastly, Inc. operates an edge cloud platform for processing, serving, and securing its customer's applications in the United States, the Asia Pacific, Europe, and internationally. The edge cloud is a category of Infrastructure as a Service that enables developers to build, secure, and deliver digital experiences at the edge of the internet. It is a programmable platform designed for web and application delivery. The company offers Compute@Edge; network services to speed up and optimize the delivery of web and application traffic; device detection and geolocation; content delivery network, such as dynamic site acceleration, origin shield, instant purge, surrogate keys, programmatic control, content compression, reliability, and modern protocols and performance services; and streaming solutions and services, including live streaming and media shield. It also provides edge security solutions, such as DDoS protection, next-gen WAF, bot protection, API and ATO protection, advanced rate limiting, and compliance services; transport layer security (TLS) and platform TLS; and origin connect. In addition, the company offers edge applications, such as load balancers and image optimizers; video on demand; and edge delivery services. It serves customers operating in digital publishing, media and entertainment, technology, online retail and education, SaaS, travel and hospitality, and financial services industries. The company was formerly known as SkyCache, Inc. and changed its name to Fastly, Inc. in May 2012. Fastly, Inc. was incorporated in 2011 and is headquartered in San Francisco, California.
NYSE ended the session with Fastly sliding 8.78% to $16.93 on Friday, after three sequential sessions in a row of gains. NYSE rose 0.71% to $16,075.98, following the last session’s upward trend on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Fastly has a trailing twelve months EPS of $-1.24.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.16%.
Moving Average
Fastly’s worth is under its 50-day moving average of $17.17 and above its 200-day moving average of $16.56.
Volatility
Fastly’s last week, last month’s, and last quarter’s current intraday variation average was 0.73%, 1.44%, and 3.31%.
Fastly’s highest amplitude of average volatility was 1.26% (last week), 4.42% (last month), and 3.31% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Fastly’s EBITDA is 5.1.
Sales Growth
Fastly’s sales growth is 16.8% for the current quarter and 15% for the next.
More news about Fastly.
7. Sol-Gel Technologies Ltd. (SLGL) – -8.76%
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
NASDAQ ended the session with Sol-Gel Technologies Ltd. falling 8.76% to $1.25 on Friday, following the last session’s downward trend. NASDAQ slid 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Sol-Gel Technologies Ltd. has a trailing twelve months EPS of $-1.09.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -62.22%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Sol-Gel Technologies Ltd.’s EBITDA is -2.64.
Volume
Today’s last reported volume for Sol-Gel Technologies Ltd. is 11433 which is 53.79% above its average volume of 7434.
Revenue Growth
Year-on-year quarterly revenue growth declined by 18.4%, now sitting on 1.21M for the twelve trailing months.
More news about Sol-Gel Technologies Ltd..
8. NeuroMetrix (NURO) – -8.51%
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NASDAQ ended the session with NeuroMetrix sliding 8.51% to $3.75 on Friday, following the last session’s upward trend. NASDAQ dropped 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-5.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.61%.
Volume
Today’s last reported volume for NeuroMetrix is 292052 which is 3640.42% above its average volume of 7808.
Moving Average
NeuroMetrix’s worth is way below its 50-day moving average of $4.72 and way under its 200-day moving average of $8.15.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NeuroMetrix’s stock is considered to be overbought (>=80).
More news about NeuroMetrix.
9. SiNtx Technologies (SINT) – -8.16%
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
NASDAQ ended the session with SiNtx Technologies falling 8.16% to $0.36 on Friday while NASDAQ slid 0.23% to $14,226.22.
Earnings Per Share
As for profitability, SiNtx Technologies has a trailing twelve months EPS of $-30.81.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -98.45%.
Yearly Top and Bottom Value
SiNtx Technologies’s stock is valued at $0.36 at 01:32 EST, way under its 52-week high of $15.10 and higher than its 52-week low of $0.34.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 97.8% and 55.8%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SiNtx Technologies’s stock is considered to be overbought (>=80).
More news about SiNtx Technologies.
10. DouYu (DOYU) – -7.96%
DouYu International Holdings Limited, together with its subsidiaries, operates a platform on PC and mobile apps that provides interactive games and entertainment live streaming services in the People's Republic of China. Its platform connects game developers and publishers, professional eSports teams or players and eSports tournament organizers, advertisers, and viewers. The company also sponsors professional players and teams, and organizes eSports tournaments. In addition, it streams other content to include a spectrum of live streaming entertainment options, such as talent shows, music, outdoor, and travel. Further, the company records and offers video clips to allow users to watch replays of selective live streaming content. DouYu International Holdings Limited was founded in 2014 and is headquartered in Wuhan, the People's Republic of China.
NASDAQ ended the session with DouYu falling 7.96% to $0.72 on Friday, following the last session’s upward trend. NASDAQ dropped 0.23% to $14,226.22, following the last session’s downward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, DouYu has a trailing twelve months EPS of $0.03.
PE Ratio
DouYu has a trailing twelve months price to earnings ratio of 24. Meaning, the purchaser of the share is investing $24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.86%.
More news about DouYu.
Stay up to date with our winners and losers daily report
